Prescription Drug Prices Review Board Act of 1993 - Establishes in the Food and Drug Administration the Patented Medicine Prices Review Board which shall have the power to decrease the length of term of a prescription drug patent if, after notice and a hearing, it is found that the drug's price is excessive. Defines the term excessive price. Allows the Board to require the recapture of tax benefits provided to the patentee of an excessively priced drug.
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the House Committee on Judiciary.
Referred to the House Committee on Ways and Means.
Sponsor introductory remarks on measure. (CR H658-659)
Referred to the Subcommittee on Health and the Environment.
Sponsor introductory remarks on measure. (CR E760)
Sponsor introductory remarks on measure. (CR E1152-1153)
Sponsor introductory remarks on measure. (CR H2486)
Sponsor introductory remarks on measure. (CR E1273)
Sponsor introductory remarks on measure. (CR E1346)
Sponsor introductory remarks on measure. (CR E1419-1420)
Sponsor introductory remarks on measure. (CR E1486)
Sponsor introductory remarks on measure. (CR E1532-1533)
Sponsor introductory remarks on measure. (CR E1539)
Sponsor introductory remarks on measure. (CR E1598)
Sponsor introductory remarks on measure. (CR E1745-1746)
Referred to the Subcommittee on Intellectual Property and Judicial Administration.
Sponsor introductory remarks on measure. (CR E1889)
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line